NASDAQ:BCTX

BriaCell Therapeutics Competitors

$2.89
-0.23 (-7.37 %)
(As of 04/20/2021 05:14 PM ET)
Add
Compare
Today's Range
$2.81
Now: $2.89
$3.09
50-Day Range
$3.15
MA: $3.75
$5.21
52-Week Range
$2.81
Now: $2.89
$8.50
Volume560,730 shs
Average Volume929,568 shs
Market Capitalization$2.23 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

BriaCell Therapeutics (NASDAQ:BCTX) Vs. ABCL, ABCM, SANA, SEER, NUVB, and IBRX

Should you be buying BCTX stock or one of its competitors? Companies in the industry of "biotechnology" are considered alternatives and competitors to BriaCell Therapeutics, including AbCellera Biologics (ABCL), Abcam (ABCM), Sana Biotechnology (SANA), Seer (SEER), Nuvation Bio (NUVB), and ImmunityBio (IBRX).

BriaCell Therapeutics (NASDAQ:BCTX) and AbCellera Biologics (NASDAQ:ABCL) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, dividends, analyst recommendations and valuation.

Profitability

This table compares BriaCell Therapeutics and AbCellera Biologics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
BriaCell TherapeuticsN/AN/AN/A
AbCellera BiologicsN/AN/AN/A

Analyst Recommendations

This is a summary of current ratings and recommmendations for BriaCell Therapeutics and AbCellera Biologics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
BriaCell Therapeutics0000N/A
AbCellera Biologics00503.00

AbCellera Biologics has a consensus target price of $52.80, suggesting a potential upside of 90.27%. Given AbCellera Biologics' higher possible upside, analysts clearly believe AbCellera Biologics is more favorable than BriaCell Therapeutics.

Valuation and Earnings

This table compares BriaCell Therapeutics and AbCellera Biologics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BriaCell TherapeuticsN/AN/AN/AN/AN/A
AbCellera BiologicsN/AN/AN/AN/AN/A

Summary

AbCellera Biologics beats BriaCell Therapeutics on 2 of the 2 factors compared between the two stocks.

Abcam (NASDAQ:ABCM) and BriaCell Therapeutics (NASDAQ:BCTX) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, valuation, profitability, dividends, earnings, institutional ownership and risk.

Profitability

This table compares Abcam and BriaCell Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AbcamN/AN/AN/A
BriaCell TherapeuticsN/AN/AN/A

Analyst Recommendations

This is a breakdown of current ratings for Abcam and BriaCell Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Abcam04302.43
BriaCell Therapeutics0000N/A

Abcam presently has a consensus target price of $22.00, indicating a potential upside of 9.13%. Given Abcam's higher probable upside, equities research analysts plainly believe Abcam is more favorable than BriaCell Therapeutics.

Valuation and Earnings

This table compares Abcam and BriaCell Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AbcamN/AN/AN/AN/AN/A
BriaCell TherapeuticsN/AN/AN/AN/AN/A

Summary

Abcam beats BriaCell Therapeutics on 2 of the 2 factors compared between the two stocks.

BriaCell Therapeutics (NASDAQ:BCTX) and Sana Biotechnology (NASDAQ:SANA) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, earnings, analyst recommendations, institutional ownership, valuation, dividends and profitability.

Analyst Recommendations

This is a summary of current ratings and recommmendations for BriaCell Therapeutics and Sana Biotechnology, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
BriaCell Therapeutics0000N/A
Sana Biotechnology02202.50

Sana Biotechnology has a consensus target price of $40.00, suggesting a potential upside of 72.56%. Given Sana Biotechnology's higher probable upside, analysts clearly believe Sana Biotechnology is more favorable than BriaCell Therapeutics.

Valuation & Earnings

This table compares BriaCell Therapeutics and Sana Biotechnology's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BriaCell TherapeuticsN/AN/AN/AN/AN/A
Sana BiotechnologyN/AN/AN/AN/AN/A

Profitability

This table compares BriaCell Therapeutics and Sana Biotechnology's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
BriaCell TherapeuticsN/AN/AN/A
Sana BiotechnologyN/AN/AN/A

Summary

Sana Biotechnology beats BriaCell Therapeutics on 2 of the 2 factors compared between the two stocks.

Seer (NASDAQ:SEER) and BriaCell Therapeutics (NASDAQ:BCTX) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, profitability, risk, institutional ownership and analyst recommendations.

Analyst Ratings

This is a breakdown of current ratings and price targets for Seer and BriaCell Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Seer02202.50
BriaCell Therapeutics0000N/A

Seer presently has a consensus target price of $68.00, indicating a potential upside of 40.76%. Given Seer's higher probable upside, analysts clearly believe Seer is more favorable than BriaCell Therapeutics.

Valuation and Earnings

This table compares Seer and BriaCell Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SeerN/AN/AN/AN/AN/A
BriaCell TherapeuticsN/AN/AN/AN/AN/A

Profitability

This table compares Seer and BriaCell Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
SeerN/AN/AN/A
BriaCell TherapeuticsN/AN/AN/A

Summary

Seer beats BriaCell Therapeutics on 2 of the 2 factors compared between the two stocks.

BriaCell Therapeutics (NASDAQ:BCTX) and Nuvation Bio (NYSE:NUVB) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, earnings, profitability, risk and dividends.

Analyst Recommendations

This is a summary of recent ratings and target prices for BriaCell Therapeutics and Nuvation Bio, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
BriaCell Therapeutics0000N/A
Nuvation Bio00603.00

Nuvation Bio has a consensus price target of $17.40, indicating a potential upside of 69.92%. Given Nuvation Bio's higher possible upside, analysts plainly believe Nuvation Bio is more favorable than BriaCell Therapeutics.

Profitability

This table compares BriaCell Therapeutics and Nuvation Bio's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
BriaCell TherapeuticsN/AN/AN/A
Nuvation BioN/AN/AN/A

Earnings & Valuation

This table compares BriaCell Therapeutics and Nuvation Bio's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BriaCell TherapeuticsN/AN/AN/AN/AN/A
Nuvation BioN/AN/AN/AN/AN/A

Summary

Nuvation Bio beats BriaCell Therapeutics on 2 of the 2 factors compared between the two stocks.

ImmunityBio (NASDAQ:IBRX) and BriaCell Therapeutics (NASDAQ:BCTX) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, earnings, valuation, institutional ownership, dividends, analyst recommendations and risk.

Valuation and Earnings

This table compares ImmunityBio and BriaCell Therapeutics' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ImmunityBioN/AN/AN/AN/AN/A
BriaCell TherapeuticsN/AN/AN/AN/AN/A

Analyst Recommendations

This is a breakdown of current ratings and target prices for ImmunityBio and BriaCell Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ImmunityBio00103.00
BriaCell Therapeutics0000N/A

ImmunityBio presently has a consensus target price of $25.00, indicating a potential upside of 50.15%. Given ImmunityBio's higher possible upside, equities research analysts plainly believe ImmunityBio is more favorable than BriaCell Therapeutics.

Profitability

This table compares ImmunityBio and BriaCell Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ImmunityBioN/AN/AN/A
BriaCell TherapeuticsN/AN/AN/A

Summary

ImmunityBio beats BriaCell Therapeutics on 2 of the 2 factors compared between the two stocks.


BriaCell Therapeutics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
AbCellera Biologics logo
ABCL
AbCellera Biologics
1.5$27.73-6.9%$8.04 billionN/A0.00Increase in Short Interest
Abcam logo
ABCM
Abcam
1.3$20.13-0.9%$4.60 billionN/A0.00Lockup Expiration
Sana Biotechnology logo
SANA
Sana Biotechnology
1.2$23.23-2.9%$4.48 billionN/A0.00
SEER
Seer
1.2$48.31-3.5%$3.04 billionN/A0.00Increase in Short Interest
Gap Up
Nuvation Bio logo
NUVB
Nuvation Bio
2.2$10.24-7.0%$2.18 billionN/A0.00
IBRX
ImmunityBio
1.7$16.65-1.9%$1.85 billionN/A0.00
Immunocore logo
IMCR
Immunocore
1.3$37.30-5.1%$1.69 billionN/A0.00
BioAtla logo
BCAB
BioAtla
1.5$47.08-1.8%$1.61 billionN/A0.00
Cullinan Oncology logo
CGEM
Cullinan Oncology
1.3$31.30-2.5%$1.40 billionN/A0.00Analyst Report
News Coverage
Silverback Therapeutics logo
SBTX
Silverback Therapeutics
1.7$37.29-1.3%$1.32 billionN/A0.00
Nurix Therapeutics logo
NRIX
Nurix Therapeutics
1.9$29.57-0.8%$1.31 billionN/A0.00Analyst Downgrade
EWTX
Cricut
1.1$26.71-0.2%$1.27 billionN/A0.00Analyst Report
News Coverage
Gap Up
KNTE
Kinnate Biopharma
1.7$26.91-2.9%$1.20 billionN/A0.00Increase in Short Interest
Vor Biopharma logo
VOR
Vor Biopharma
1.9$27.25-4.8%$1.06 billionN/A0.00
CNTB
Connect Biopharma Holdings Limited American Depositary Shares
1.7$17.08-0.9%$962.29 millionN/A0.00Analyst Report
News Coverage
Bolt Biotherapeutics logo
BOLT
Bolt Biotherapeutics
1.6$24.34-0.2%$882.77 millionN/A0.00
FDMT
4D Molecular Therapeutics
1.3$31.93-3.4%$880.90 millionN/A0.00
Gracell Biotechnologies logo
GRCL
Gracell Biotechnologies
1.5$12.34-3.7%$839.21 millionN/A0.00Gap Up
Pharvaris B.V. logo
PHVS
Pharvaris B.V.
1.4$23.08-12.7%$828.16 millionN/A0.00
Pharming Group logo
PHAR
Pharming Group
0.0$12.90-0.4%$827.27 millionN/A0.00
iTeos Therapeutics logo
ITOS
iTeos Therapeutics
1.9$22.28-5.7%$737.78 millionN/A0.00
FNCH
Finch Therapeutics Group
2.0$14.23-8.9%$730.28 millionN/A0.00Analyst Report
News Coverage
Gap Up
ACHL
Achilles Therapeutics plc American Depositary Shares
0.0$15.76-1.6%$630.05 millionN/A0.00
Inventiva logo
IVA
Inventiva
1.4$13.27-0.9%$517.26 millionN/A0.00News Coverage
SGTX
Sigilon Therapeutics
1.4$16.00-0.4%$506.09 millionN/A0.00Gap Up
Gemini Therapeutics logo
GMTX
Gemini Therapeutics
1.7$10.84-3.5%$482.45 millionN/A0.00Gap Up
Landos Biopharma logo
LABP
Landos Biopharma
1.8$10.06-7.9%$435.28 millionN/A0.00
Terns Pharmaceuticals logo
TERN
Terns Pharmaceuticals
2.0$16.78-1.9%$429.64 millionN/A0.00
NexImmune logo
NEXI
NexImmune
2.0$18.46-0.5%$417.84 millionN/A0.00
Sensei Biotherapeutics logo
SNSE
Sensei Biotherapeutics
2.0$12.98-1.7%$403.76 millionN/A0.00News Coverage
Angion Biomedica logo
ANGN
Angion Biomedica
1.7$13.30-2.0%$400.10 millionN/A0.00Gap Up
PRTG
Portage Biotech
0.0$28.15-4.4%$355.24 millionN/A0.00Gap Up
Unity Biotechnology logo
UBX
Unity Biotechnology
1.1$4.91-5.7%$268.57 millionN/A-2.61
Kaleido Biosciences logo
KLDO
Kaleido Biosciences
1.8$6.08-1.5%$258.20 millionN/A-2.40
Decibel Therapeutics logo
DBTX
Decibel Therapeutics
2.2$9.70-1.4%$241.55 millionN/A0.00
VINC
Vincerx Pharma
1.0$16.43-4.8%$240.80 millionN/A0.00
ImmunoPrecise Antibodies logo
IPA
ImmunoPrecise Antibodies
0.0$9.22-7.2%$188.90 millionN/A0.00Increase in Short Interest
News Coverage
Gap Up
LBPH
Longboard Pharmaceuticals
1.9$10.14-0.1%$171.37 millionN/A0.00Quiet Period Expiration
GANX
Gain Therapeutics
1.7$13.50-3.5%$158.29 millionN/A0.00Analyst Report
News Coverage
Gap Down
Annovis Bio logo
ANVS
Annovis Bio
0.0$22.34-1.7%$152.49 millionN/A0.00Gap Up
EVAX
Evaxion Biotech A/S
1.7$7.16-4.3%$131.51 millionN/A0.00News Coverage
Gap Up
LGVN
Longeveron
0.3$6.02-3.5%$118.10 millionN/A0.00
CMMB
Chemomab Therapeutics
0.0$30.39-13.5%$80.60 millionN/A0.00News Coverage
UPC
Universe Pharmaceuticals
0.0$3.44-3.2%$77.21 millionN/A0.00News Coverage
VRDN
Viridian Therapeutics
1.7$15.37-2.1%$58.78 millionN/A0.00Decrease in Short Interest
Inhibikase Therapeutics logo
IKT
Inhibikase Therapeutics
0.0$5.03-3.2%$52.17 millionN/A0.00
VIRI
Virios Therapeutics
1.3$5.17-8.1%$46.57 millionN/A0.00
VIRX
Viracta Therapeutics
1.7$7.77-2.8%$39.06 millionN/A0.00
VYNT
Vyant Bio
0.0$3.35-3.3%$38.08 millionN/A0.00Gap Up
NLS Pharmaceutics logo
NLSP
NLS Pharmaceutics
1.7$3.06-4.9%$34.28 millionN/A0.00
This page was last updated on 4/20/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.